Tests LY3457263 in adults with type 2 diabetes not reaching blood sugar goal
Tests LY3457263 against placebo in adults with type 2 diabetes on semaglutide or tirzepatide.
Plain-language title generated from the registry record
Registry title: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Key facts
- Where
- Brampton, Chicoutimi, Hamilton, Longueuil, Moncton, Sarnia, Toronto, and Waterloo, CanadaSee the 9 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes whose HbA1c is still above goal while on a stable dose of semaglutide or tirzepatide.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with HbA1c from ≥7.5% (58 mmol/mol) to ≤10.5% (91 mmol/mol) and a body mass index (BMI) of ≥27 kg/m2 at screening. Stable body weight for the three months before screening.
- Earlier treatment
- Stable dose of injectable semaglutide (1 or 2 mg) or injectable tirzepatide (5, 7.5, 10, 12.5 or 15 mg) for at least three months before screening. Up to three permitted diabetes pills (metformin, SGLT2 inhibitors, alpha-glucosidase inhibitors, sulfonylurea, thiazolidinediones) are allowed if the dose was stable for at least three months.
- Biomarker or test result
- HbA1c from ≥7.5% (58 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
Main reasons for not taking part
- Type 1 diabetes, latent autoimmune diabetes, or a history of ketoacidosis or hyperosmolar coma
- Past or planned surgery for obesity
- Heart attack, stroke, unstable angina or hospital stay for heart failure in the three months before screening
- Insulin used to control blood sugar in the past year (short-term use is allowed)
- Weight-loss medicines or remedies in the three months before screening
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06897475, who can take part
Where in Canada
- Centricity Research Brampton EndocrinologyBrampton, CanadaTaking people
- Ecogene-21Chicoutimi, CanadaTaking people
- Winterberry Research Inc.Hamilton, CanadaTaking people
- Viacar Recherche CliniqueLongueuil, CanadaTaking people
- G A Research AssociatesMoncton, CanadaTaking people
- Bluewater Clinical Research Group Inc.Sarnia, CanadaTaking people
- Diabetes Heart Research CentreToronto, CanadaTaking people
- Maple Leaf ResearchToronto, CanadaTaking people
- Fadia El Boreky MedicineWaterloo, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06897475EU 2024-520328-27-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.Read full original descriptionShow less
A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Inclusion: Have type 2 diabetes; Have HbA1c ≥7.5% to ≤10.5% at screening; Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening; Have had a stable body weight for the three months prior to screening; On stable treatment dose of one of the following incretins for at least three months prior to screening:; Injectable semaglutide (1 and 2 milligram (mg)); Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg).
Exclusion: Have a prior or planned surgical treatment for obesity; Have any of the following cardiovascular conditions within three months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Have taken any medications or alternative remedies for weight loss within three months prior to screening; Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma; Have used insulin to control blood glucose within the past year (short-term use allowed); Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening; If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study.